pcDNA3.1-rpfB, pcDNA3.1-rpfD
Candidate Overview
The candidate vaccine we are developing is a recombinant plasmid DNA vaccine. Two genes from the rpfs family, namely rpfB and rpfD, were inserted full-length into the pcDNA3.1 plasmid along with the Kozak sequence, resulting in recombinant plasmids pcDNA3.1-rpfB and pcDNA3.1-rpfD. The vaccination method used on test animals is intramuscular injection of the recombinant plasmid without an adjuvant
Sponsor / Lead Developer: Department of Microbiology, Medical Faculty Universitas Indonesia
Primary Indication: Prevention of Mtb infection or sustained infection
Target Population(s): To be determined
Target Route of Administration: Intramuscular
Immune tissue localization: Lung
Immunological responses: B-cell/Antibody and T-cell
Preclinical Animal Models: Mouse
Intended to elicit trained immunity: Yes
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | T-cell B-cell/Antibody |
|
| T-cell phenotype | CD8 | |
| T-cell functional profile | IL-12 | IFN-γ |
| Characteristics of B-cell response | Subclass IgG2a in mice which is equal with IgG1 in human. | |
| Preferential immune tissue localization | Lung |
|
| Trained immunity | Yes | |
Related Publications
- pcDNA3.1-rpfB or pcDNA3.1-rpfD recombinant DNA prevents Mycobacterium tuberculosis infection in BALB/c mice. (J. Immunoass. Immunochem, 2026)
- Evaluation of Tuberculosis Vaccine Candidate, pcDNA3.1-rpfD using Mycobacterial Growth Inhibition Assay (MGIA). (HAYATI J. Biosci., 2022)
- Efficacy of Tuberculosis Vaccine Candidate pcDNA3.1-rpfB in Inhibiting the Growth of Mycobacterium tuberculosis In Vitro with Mycobacterial Growth Inhibition Assay. (Makara J. Sci., 2022)